Evaluation of four HIV antigen tests

Area of Science:

• Virology
• Immunology
• Clinical Diagnostics

Background:

• Accurate HIV antigen assays are crucial for monitoring treatment efficacy, especially in resource-limited settings.
• Previous studies have compared limited numbers of HIV antigen detection methods.
• Evaluating multiple commercial assays is necessary for informed laboratory choices.

Purpose of the Study:

• To directly compare the performance of four different commercial HIV antigen assays.
• To identify the most sensitive and reliable assay for HIV p24 antigen detection in patient follow-up.

Main Methods:

• Evaluation of four commercial HIV-1 p24 antigen assays: COULTER HIV-1 p24 Antigen Assay, INNOTEST HIV Antigen mAb, Genetic Systems HIV-1 Ag EIA, and VIDAS HIV P24 II.
• Testing of 88 plasma and cell culture supernatant samples from 35 HIV-infected patients across all infection stages.
• Assessment of sensitivity, specificity, and performance in detecting p24 antigen in patient follow-up samples.

Main Results:

• INNOTEST HIV Antigen mAb (Test 2) exhibited the highest sensitivity, detecting p24 antigen in 85.7% of patients and 84.9% of samples.
• Genetic Systems HIV-1 Ag EIA (Test 3) and VIDAS HIV P24 II (Test 4) showed moderate sensitivity, while COULTER HIV-1 p24 Antigen Assay (Test 1) was the least sensitive.
• Test 2 also demonstrated superior performance in detecting genetically diverse HIV isolates.

Conclusions:

• INNOTEST HIV Antigen mAb is the most sensitive assay among the four evaluated for HIV p24 antigen detection.
• The findings support the use of INNOTEST HIV Antigen mAb for reliable and sensitive HIV patient monitoring, particularly in developing countries.
• Selecting the appropriate HIV antigen assay is critical for accurate diagnosis and patient management.